Poniard Pharmaceuticals, Inc.
7000 Shoreline Court
Suite 270
South San Francisco,
CA 94080
United States - Map
Phone: 650-583-3774
Fax: 650-583-3789
Web Site: http://www.poniard.com
| Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006. Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Gerald McMahon Ph.D., 54
Chairman and Chief Exec. Officer |
N/A
| N/A | Mr. Ronald A. Martell , 47
Pres, Chief Operating Officer |
N/A
| N/A | Dr. Robert L. De Jager M.D., F.A.C.P., 67
Chief Medical Officer |
$
391.00K | N/A | Ms. Anna Lewak Wight J.D., CLP, 54
VP of Legal and Sec. |
N/A
| N/A | Mr. Gregory L. Weaver CPA, M.B.A, 52
Chief Financial Officer and Sr. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.01% Nasdaq 
0.01 (0.55%) 
Profile
